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Subunit composition of N-methyl-D-aspartate–type glutamate recep-
tors (NMDARs) dictates their function, yet the ontogenic profiles of
human NMDAR subunits from gestation to adulthood have not been
determined. We examined NMDAR mRNA and protein development
in human dorsolateral prefrontal cortex (DLPFC), an area in which
NMDARs are critical for higher cognitive processing and NMDAR
hypofunction is hypothesized in schizophrenia. Using quantitative re-
verse transcriptase–polymerase chain reaction and western blotting,
we found NR1 expression begins low prenatally, peaks in ad-
olescence, yet remains high throughout life, suggesting lifelong
importance of NMDAR function. In contrast, NR3A levels are low
during gestation, surge soon after birth, and decline progressively
through adolescence and into adulthood. Because NR3A subunits
uniquely attenuate NMDAR-mediated currents, limit calcium influx,
and suppress dendritic spine formation, high levels during early
childhood may be important for regulating neuroprotection and
activity-dependent sculpting of synapses. We also examined whether
subunit changes underlie reduced NMDAR activity in schizophrenia.
Our results reveal normal NR1 and NR3A protein levels in DLPFC
from schizophrenic patients, indicating that NMDAR hypofunction is
unlikely to be maintained by gross changes in NR3A-containing
NMDARs or overall NMDAR numbers. These data provide insights
into NMDAR functions in the developing CNS and will contribute to
designing pharmacotherapies for neurological disorders.
Keywords: antipsychotic, DLPFC, glutamate, postmortem, schizophrenia
Introduction
N-methyl-D-aspartate (NMDA)–type ionotropic glutamate
receptors (NMDARs) are involved in a wide array of biological
processes crucial for brain development and function. In addi-
tion to modulating neuronal and synapse maturation in develop-
ment (Perez-Otano and Ehlers 2004), NMDARs are responsible
for short-term and long-term memory storage through mech-
anisms of synaptic plasticity (Malenka and Nicoll 1999). For
example, many executive functions and working memory tasks
require NMDAR activity in the prefrontal cortex (PFC) (Lisman
et al. 1998; Durstewitz and Gabriel 2007), suggesting that
disruption of these receptors could cause profound cognitive
deficits (Goldman-Rakic 1995; Lewis 1997). Given the diverse
roles of NMDARs, it is not surprising that NMDAR dysfunction
is thought to underlie several neurological and psychiatric
disorders. Accordingly, a major goal in neuroscience is to
understand how NMDARs normally change during human
development and how this might be altered in disease states.
NMDAR function is dictated by its subunit composition
(Monyer et al. 1992). NMDARs are tetramers consisting of
essential NR1 subunits in combination with NR2 (A-D) or NR3
(A-B) subunits that provide functional molecular diversity
(Perez-Otano et al. 2001; Al-Hallaq et al. 2002; Matsuda et al.
2003). However, unlike the conventional NR1/NR2 receptors,
those containing the recently identified NR3 subunits exhibit
decreased single-channel conductance, insensitivity to magne-
sium blockade, and reduced calcium (Ca2
+
) permeability (Das
et al. 1998; Perez-Otano et al. 2001; Chatterton et al. 2002;
Sasaki et al. 2002). Because Ca2
+
influx is responsible for many
forms of synaptic plasticity (Malenka and Bear 2004) and
excitotoxic cell death (Choi 1988), the inclusion of NR3
subunits into NMDARs is likely to critically regulate the
properties of NMDAR-mediated plasticity and may also serve
a neuroprotective role.
Developmental regulation of human NMDAR subunits is poorly
understood. Such knowledge is important for the rational
design of pharmacotherapies for diseases involving NMDAR
subunit dysfunction, such as neurodegenerative conditions,
stroke, epilepsy, neuropathic pain, and schizophrenia (re-
viewed in Cull-Candy et al. 2001; Waxman and Lynch 2005;
Kristiansen et al. 2007). For example, existing treatments for
schizophrenia are very limited in their specificity and efficacy
(Ross et al. 2006). This disease is thought to arise from de-
creased NMDAR activity that disrupts normal synaptic connec-
tivity and plasticity, especially within the dorsolateral
prefrontal cortex (DLPFC) (Javitt and Zukin 1991; Olney
et al. 1999; Lewis and Levitt 2002; Coyle et al. 2003; Frankle
et al. 2003). Although there is little consistent evidence that
overall NR1 and NR2 levels differ between schizophrenic
patients and controls (Kristiansen et al. 2007), a recent study
suggests that NR3A may be elevated within the schizophrenic
DLPFC (Mueller and Meador-Woodruff 2004). Therefore,
NR3A’s unique ability to suppress NMDAR function makes it
an extremely attractive candidate both as an endogenous
contributor to the NMDAR hypofunction observed in schizo-
phrenia and as a potential target for pharmacological inter-
ventions.
To reveal how NMDAR subunit composition changes through
the course of brain development and to begin to understand
whether NMDAR subunits are altered in schizophrenia, we
used postmortem tissue to examine NMDAR subunits, NR3A
and NR1, during normal human DLPFC development and in the
DLPFC of schizophrenic patients. Additionally, we demonstrate
the effects of antipsychotic medications on NMDAR subunits.
To our knowledge, we provide the first systematic evaluation of
the normal developmental profiles of NMDAR expression in
maturation of the human PFC from midgestation to early
adulthood.
 The Author 2008. Published by Oxford University Press. All rights reserved.
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Materials and Methods
Postmortem Human Samples
Postmortem human tissue samples were deidentified to protect
personal health information. Samples from the developmental cohort
contained uniform 1-cm coronal sections of PFC (Brodmann areas 9/
46) from 45 subjects ranging in age from 18 weeks gestation through
25 years (Table 1). Frozen tissue was obtained from the National
Institute of Child Health and Human Development–University of
Maryland (UMD) Brain and Tissue Bank for Developmental Disorders
under contracts N01-HD-4-3368 and N01-HD-4-3383. Individuals died
from non-CNS causes and had no known history of substance abuse or
major psychiatric disorders. A priori, samples were divided into 7 age
groups established in a previous study (Glantz et al. 2007): prenatal
(n = 6), birth to 12 months of age (n = 5), 1–5 years (n = 6), 6–10 years
(n = 6), 11–15 years (n = 11), 16–20 years (n = 4), and 21–25 years
(n = 7). The schizophrenia cohort consisted of Brodmann area 9 tissue
samples from 35 subjects (control n = 20; schizophrenia n = 15)
obtained from the Harvard Brain Tissue Resource Center (McLean
MA; supported in part by PHS grant number R24 MH068855), with ages
ranging from 21 to >80 years (Table 2). To protect personal health
information, exact ages were used for statistical purposes, but only age
ranges of subjects can be published. PFC samples in the schizophrenia
and control groups were group matched for age, gender, ethnicity,
side-of-brain, brain pH, and postmortem interval (PMI). All fresh-frozen
tissue blocks from the UMD and Harvard collections were chipped
from larger frozen cortical slabs and consisted primarily of gray matter
with small amounts of underlying white matter. The samples from the
UMD tissue collection were harvested as 1-cm coronal slabs. Cuts were
made with guidance from a neuroanatomical atlas to select Brodmann
areas 9 and 46 and immediately frozen at –80 C. Cytoarchitectonic
localizations of Brodmann areas 9 and 46 were ascertained using Nissl
staining of sections cut immediately adjacent to tissue blocks used for
this study (see Glantz et al. 2007 for details). Samples of Brodmann area
9 from the Harvard tissue were obtained through uniform dissection
from the superior prefrontal gyrus according to the Brodmann map. All
tissues were stored frozen at –80 C until use. Tissue pH was measured
as described (Salimi et al. forthcoming) and samples with pH <5.8 were
excluded from analysis. This study was approved by the Biomedical
Institutional Review Board of the University of North Carolina at Chapel
Hill (UNC-CH).
Animal Use
The animal use in this study was approved by the Institutional Animal
Care and Use Committee of the UNC-CH. All rodents were maintained
and sacrificed according to protocol guidelines.
Postmortem Stability of NMDAR Proteins
Eighteen C57BL/6 mice at age postnatal day 10 (P10) were divided into
3 equal groups, anesthetized with a lethal dose of sodium pentobarbital,
and decapitated upon disappearance of corneal reflexes. In the first
group, frontal cortex was dissected and immediately frozen at –80 C
(PMI = 0 h). To approximate the human PMI and simulate morgue
conditions, heads of the second and third groups were kept at room
temperature for 6 h, then at 4 C for 6 h and 18 h, respectively, after
which time frontal cortices were dissected (PMI = 12 h and PMI = 24
h) and frozen at –80 C until use in immunoblotting analysis (Jarskog
et al. 2004).
Antipsychotic Treatment
Subchronic drug treatments were administered to 36 singly housed,
male Sprague–Dawley rats (150–200 g, Charles River) as described
previously (Jarskog et al. 2007). Briefly, animals received daily intra-
peritoneal injections of haloperidol (1 mg/kg/day, n = 12), clozapine
(10 mg/kg/day, n = 12), or saline (0.9%, n = 12) for 4 weeks. One hour
after the final dose, rats were killed and anterior right medial frontal
cortices were dissected. All tissue was kept frozen at –80 C until use in
immunoblotting analysis.
RNA Extraction, cDNA Preparation, and Quantitative Reverse
Transcriptase–Polymerase Chain Reaction
Total RNA was extracted from pulverized human developmental PFC
tissue samples using the RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. RNA concentrations
and quality (mean RNA Integrity Number = 8.75 ± 1.0) were de-
termined using Series II RNA 6000 Nano Assay in the Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA). RNA was reverse transcribed
using the High Capacity cDNA RT Kit (Applied Biosystems, Foster City,
CA) according to the manufacturer’s protocol. Relative expression
levels of NMDAR mRNAs were measured by quantitative reverse
transcriptase–polymerase chain reaction (RT-PCR) using prevalidated
assays for NR1, NR3A, and b-glucuronidase (GUSB), the latter of which
served as the endogenous control (Applied Biosystems Assays-on-
Demand: Hs00609557_m1 for NR1, Hs00370290_m1 for NR3A, and
4333767F for GUSB). All probes had 6-carboxy-fluorescein phosphor-
amidite fluorescent reporter dye and minor groove binder (MGB)
quencher. The NR1 primer–probe combination spanned exon bound-
ary 1–2, covering all 8 splice variants, and the NR3A assay covered exon
boundary 3–4. Pilot experiments using cDNA dilutions were used to
define the dynamic range of each assay. GUSB was selected from several
candidate reference genes as the endogenous control most closely
matching in expression level to the target NMDAR genes. Reactions
Table 1
Developmental study demographics
Age group (years) Age (years) Subjects PMI (h) pH Storage time (years) Race Sex
\0 0.41 ± 0.0 6 1.0 ± 0.0 6.1 ± 0.2 13.6 ± 0.8 1 C, 5 AA 3 M, 3 F
0–1 0.1 ± 0.1 5 7 ± 3.2 6.3 ± 0.4 10.3 ± 2.9 2 C, 3 AA 3 M, 2 F
1–5 3.4 ± 1.6 6 15.2 ± 4.8 6.1 ± 0.3 6.1 ± 1.1 2 C, 4 AA 2 M, 4 F
6–10 8.3 ± 0.8 6 19.8 ± 9.8 6.3 ± 0.3 5.0 ± 0.8 3 C, 3 AA 2 M, 4 F
11–15 13.3 ± 1.0 11 18.3 ± 6.1 6.4 ± 0.3 7.3 ± 3.7 5 C, 3 AA, 3 U 9 M, 2 F
16–20 18.1 ± 1.7 4 14.8 ± 5.4 6.1 ± 0.1 9.3 ± 4.0 1 C, 3 AA 3 M, 1 F
21–25 23.1 ± 1.6 7 14.7 ± 5.9 6.2 ± 0.2 6.5 ± 1.5 2 C, 4 AA 6 M, 1 F
Note: Characteristics of normal subjects. Means are reported as ±standard deviation. C, Caucasian; AA, African-American; U, unknown; M, male; and F, female.
Table 2
Schizophrenia study demographics
Diagnosis Subjects Age (years) PMI (h) pH Storage time (years) Race Sex
Control 20 56.7 ± 18.3 21.2 ± 6.0 6.4 ± 0.3 6.1 ± 1.5 9 C, 11 U 15 M, 5 F
Schizophrenia 15 54.3 ± 17.0 21.7 ± 5.1 6.4 ± 0.3 7.8 ± 1.2 14 C, 1 U 10 M, 5 F
Note: Characteristics of normal control and schizophrenic subjects. Means are reported as ±standard deviation. C, Caucasian; AA, African-American; U, unknown; M, male; and F, female.
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were run in a 384-well plate format on an ABI 7900HT Fast RT-PCR
sequence detection system (Applied Biosystems). Each 20-ll reaction
contained 9 ll diluted cDNA (NR1: 6.25 ng; NR3A: 12.5 ng; GUSB: 6.25 ng
or 12.5 ng), 0.9 lM each primer, 0.25 lM probe, and 10 ll TaqMan
Universal PCR 23 MasterMix with AmpErase UNG (Applied Biosystems)
withMGB/TAMRA 5# endonuclease and ROXpassive reference dye. PCR
cycle parameters were 50 C for 2 min, 95 C for 10 min, 40 cycles of 95
C for 15 s, 60 C for 60 s. Each examined mRNA was quantified from
a single plate, and CT values were within the linear range of the standard
curve. All samples were loaded in triplicates. RT was omitted from
control reactions for each tissue sample to verify the absenceof amplified
genomic DNA. The same threshold and baseline were used for all
samples. Three of the 45 human brain samples did notmeet our inclusion
criteria for themRNAquantification andwere thus omitted from analysis.
Cortical Brain Extracts
Homogenates were prepared from postmortem human, monkey,
mouse, and rat frontal cortices. Tissues were homogenized (1:10, w/
v) on ice for 30 s (PowerGen 125, Fisher Scientific, Pittsburgh, PA) and
sonicated for 10 s at 10 mV (Sonic Dismembrator 60, Fisher Scientific)
in ice-cold 50 mM Tris-HCl buffer (pH 7.4) with 0.6 M NaCl, 0.2% Triton
X-100, 1 mM benzamidine, 0.1 mM benzethonium chloride, and 0.1 mM
phenylmethylsulfonyl fluoride (Sigma, St Louis, MO). Samples were
cleared of debris by centrifugation at 4 C for 15 min at 15 000 3 g, and
supernatants were assayed for total protein in triplicate using the
bicinchoninic acid method (Micro BCA Protein Assay Kit, Pierce
Chemical, Rockford, IL). Aliquots were stored at –80 C until use.
Quantitative Immunoblotting
Equal amounts of total protein (25–50 lg) were heated for 10 min at
70 C in sample buffer and applied to 10-lane 4–12% gradient NuPAGE
Novex Tris-glycine mini-gels (Invitrogen, Carlsbad, CA), along with
molecular weight markers, a pooled sample homogenate, and a mouse
frontal cortex sample as positive control. Coded samples were loaded
randomly onto gels to preserve the integrity of blinded, unbiased
data analyses. Samples were resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis at 125 V for 2 h. Separated proteins
were then electrophoretically transferred (Bio-Rad, Hercules, CA) to
nitrocellulose membranes (Millipore, Billerica, MA) at 25 V overnight at
4 C. After eliminating nonspecific protein binding to membranes with
blocking buffer (Odyssey, LI-COR, Lincoln, NE) for 1 h at room
temperature, membranes were cut into 3 strips with the aid of molec-
ular size markers. Because the Odyssey Imaging System uses 2 near-
infrared channels to detect fluorescent signals, 2 proteins can be
simultaneously probed on each blot strip. Thus, 6 proteins were able to
be detected from the same gel (upper blot strip, NR2B/NR2A; middle,
NR3A/NR1; lower, b-tubulin/GAPDH). This approach allowed us to
analyze multiple proteins while avoiding complications arising from
stripping and reprobing membranes. The following primary antibodies
were incubated overnight at 4 C in 1:1 blocking buffer:phosphate-
buffered saline (PBS), at optimized concentrations: rabbit anti-pan NR1
(#SC9058, 1:6000, Santa Cruz Biotechnology, Santa Cruz, CA), mouse
anti-NR1 (#556308, 1:5000, BD/Pharmingen, San Jose, CA), rabbit anti-
NR2A (#SC9056, 1:500, Santa Cruz), goat anti-NR2B (#SC1469,
1:10,000, Santa Cruz), mouse anti-NR3A (#MAB5388, 1:1000, Chem-
icon, Temecula, CA), rabbit anti-NR3A (#07-356, 1:500, Millipore/
Upstate), goat anti-GAPDH (#IMG3073, 1:40,000, Imgenex, San Diego,
CA), and mouse anti-b-tubulin (#MAB3408, 1:100,000, Millipore/
Chemicon). Membranes were washed extensively in PBS-0.1% Tween
20 and then incubated at room temperature for 1 h (shielded from
light) with appropriate secondary antibodies diluted in 1:1 blocking
buffer/PBS-0.1% Tween 20: Alexa Fluor 680-labeled anti-goat IgG or
anti-mouse IgG (1:5000, Molecular Probes/Invitrogen), and IRDye 800-
labeled anti-rabbit IgG (1:3000, Rockland Immunochemicals, Gilberts-
ville, PA). Membranes were washed and fluorescent signals measured
directly on the Odyssey Infrared Imaging System (LI-COR). Band
density analysis was performed using Odyssey software (v2.1) supplied
by the manufacturer. Antibody specificities for the following have been
previously established: rabbit anti-pan NR1 (Fernandez-Monreal et al;
Miyamoto et al. 2005; Offenhauser et al. 2006; Talbot et al. 2006; Li et al.
2007), mouse anti-NR1 (Siegel et al. 1994; 1995; Wood et al. 1995; Lack
et al. 2005; Stepulak et al. 2005; Perez-Otano et al. 2006; Welch et al.
2007), rabbit anti-NR3A (Ishihama and Turman 2006), rabbit anti-NR2A
(Miyamoto et al. 2005; Yashiro et al. 2005), and goat anti-NR2B (May
et al. 2004; Pawlak et al. 2005; Yashiro et al. 2005; Czaja et al. 2006).
Mouse anti-NR3 antibody produces no band at the expected molecular
weight (~130 kD) in NR3A knockout versus wild-type cortical
homogenates (data not shown). Antibody signal intensities were
collected from 3 separate experiments for each sample. A standard
curve of increasing protein amounts of pooled sample was immuno-
blotted for each protein to ensure a linear relationship between
increasing total protein amounts and density of the respective bands
(data not shown).
Data Collection and Statistical Analyses
To assess mRNA levels for each human target gene, GUSB was used as
the internal reference gene and relative quantities were obtained by
the DDCT method using Sequence Detection Software (SDS v.2.2.2,
Applied Biosystems). Western blot experiments measured antibody
signal intensities in postmortem tissue, interleaving control and experi-
mental conditions where appropriate. A pooled sample was run on
each gel, and the band density of each experimental sample was mea-
sured relative to this reference standard to permit intergel compar-
isons. Samples were run in triplicate experiments, and individual
antibody values for each sample were averaged.
Developmental age group or diagnosis group means were calculated
from individual averages. Group means were normalized either to the
mean level of expression for the maximally expressing age group
(developmental studies) or to the control group (schizophrenia and
antipsychotic drug studies). For multiple group comparisons, 1-way
analyses of variance (ANOVAs) were performed, followed by between-
group comparisons with Tukey–Kramer tests. Unpaired Student’s t-tests
were used to compare diagnosis between schizophrenic subjects and
normal controls with NMDAR proteins as variables. Two-way ANOVAs
were performed post hoc to probe interactions between diagnosis and
sex. All levels of significance represent 2-tailed values. Statistical
analyses were conducted using Graphpad Instat (San Diego, CA) and
SAS (Cary, NC). Developmental brain tissues binned into 7 groups based
on age were not significantly different with regard to pH or sex;
however, significant differences were observed between the groups
due to PMI (ANOVA, F6,38 = 8.11, P < 0.0001) and storage time
(ANOVA, F6,38 = 8.08, P < 0.0001) (see Table 1). Therefore, we included
PMI and storage time in secondary analysis of covariance (ANCOVA)
analyses with these variables as covariates. Although brain tissues from
normal controls and schizophrenic patients had no significant differ-
ences between groups with regard to age, pH, or PMI, a significant
difference was detected between the groups due to storage time. No
secondary analyses were performed for the schizophrenia study.
Results
NR1 and NR3A, but not NR2A and NR2B, Protein Levels
Can Be Studied Effectively in Postmortem Tissue
A difficulty of studying human tissue is that protein degradation
occurs during the PMI after death and prior to tissue pre-
servation. Therefore, it is necessary to assess how PMI affects
antibodies’ recognition of target sites. To test this, we used a
mouse model to mimic the decay of human tissue under simu-
lated morgue conditions (Jarskog et al. 2004). Protein integrity
was measured by immunoblotting of cortical homogenates run
in triplicate (Fig. 1). Antibodies directed against NMDA recep-
tor subunits NR3A (125 kD), NR2A (165 kD), and NR2B (170
kD), as well as loading controls, b-tubulin (55 kD) and GAPDH
(36 kD), all detected single bands at the appropriate molecular
weights, consistent with predicted sizes. The double band for
NR1 (116 kD) may be the result of splice variants, deglycosy-
lation, or proteolytic cleavage products (Monyer et al. 1992;
2562 NR3A and NRI in Human Development d Henson et al.
Brose et al. 1993; Sheng et al. 1994; Zukin and Bennett 1995;
Luo et al. 1996).
Immunoblotting revealed that NR1 and NR3A proteins dis-
played modest and predictable decreases in band densities, with
no main effects noted by ANOVA (NR1, n = 4/group, F2,9 =
3.01, P = 0.10; NR3A, n = 4/group, F2,9 = 2.89, P = 0.11).
Moderate protein degradation was also observed for the
loading controls, although the decrease in b-tubulin reached
statistical significance (b-tubulin, n = 4/group, F2,9 = 6.27,
P = 0.02; GAPDH, n = 2/group, F2,3 = 7.06, P = 0.07). Unlike
NR1 and NR3A, however, degradation of both NR2A and NR2B
subunits was substantial and progressive, with total decreases
in signal intensities of 69% and 75%, respectively. ANOVA
demonstrated that there was a main effect of PMI on NR2A and
NR2B levels (NR2A, n = 4, F2,9 = 18.91, P < 0.001; NR2B, n = 4,
F2,9 = 30.74, P < 0.0001), and post hoc analyses revealed that
protein levels were significantly reduced at both 12 and 24 h
PMI compared with baseline (PMI = 0 h) values. This effect of
PMI on NR2A and NR2B is consistent with the rapid proteolysis
of NR2 subunits soon after death in human tissue (Wang et al.
2000) and is also consistent with difficulties in reliably mea-
suring NR2A and NR2B levels in rhesus monkeys (O’Connor
et al. 2006) and in human tissue (current study, data not shown).
For these reasons, we performed no further analyses of NR2A
and NR2B in human tissue. Furthermore, to minimize problems
arising from studying tissue taken after a long PMI, we limited
our analysis to tissue with a relatively low PMI (mean PMI ~13
and 21 h for the developmental and schizophrenia studies,
respectively).
Our mouse data indicate that NR1 and NR3A subunits
exhibit relatively high postmortem stability ( >65%) for at least
24 h, suggesting that they are also likely to be more stable in
human tissue than NR2 subunits. Importantly, our pilot experi-
ments demonstrated that in both mouse and human tissue, the
NR1 and NR3A antibodies recognized bands consistent with
predicted sizes at 116 kD and ~130 kD, respectively. This
indicates that these antibodies similarly recognize mouse and
human NMDAR subunit homologues at their expected molec-
ular weights. Assuming the postmortem stability of these
proteins is similar in mice and humans, our data indicate that
the NR1 and NR3A antibodies used in this study are appropriate
to study these NMDAR subunits in human postmortem tissue.
In addition to PMI, another important consideration in
western blotting of postmortem tissue is accurate protein band
measurement. Typically, signal intensity for the protein of
interest is measured relative to an in-lane reference, a loading
control such as GAPDH or b-tubulin. However, as both of these
common proteins varied considerably in their expression levels
across development (data not shown), they were inappropriate
for our studies. To overcome this limitation, we instead stan-
dardized protein levels of each sample to a homogenate pool
that was included on every gel as a reference (see Materials and
Methods) and allowed for intergel comparisons. Other studies
have found similar methods to be reliable alternatives for
quantification (Quinlan et al. 1999; Folkerth et al. 2004; Haynes
et al. 2005; Murphy et al. 2005; Glantz et al. 2007; Salimi et al.
forthcoming). GAPDH and b-tubulin normalizations were then
used only for confirmatory analyses of adult samples in the
schizophrenia study (Supplementary Figs S4 and S5), which had
similar levels of these loading control proteins across groups.
Thus, unless otherwise noted, all analyses were performed on
protein levels standardized to the pooled sample that was run
on each gel. Moreover, protein data from each sample was
averaged from 3 independent western blotting experiments, as
this further eliminated the possibility of loading errors.
Developmental Expression of NR3A Peaks in Early
Childhood in Human DLPFC
Studies in rodents indicate that expression of the nonconven-
tional NMDAR subunit, NR3A, is upregulated soon after birth,
peaks during early postnatal life (around postnatal day 7; P7),
and then decreases through the subsequent weeks in many
regions of the brain (Ciabarra et al. 1995; Sucher et al. 1995; Das
et al. 1998; Sun et al. 1998; Al-Hallaq et al. 2002; Sasaki et al.
2002; Wong et al. 2002; Ishihama and Turman 2006; Perez-
Otano et al. 2006). We hypothesized that NR3A expression in
humans is also upregulated early in development and down-
regulated in adolescence. To test this, we determined NR3A
transcript levels by quantitative RT-PCR of postmortem human
tissue from individuals aged 18 weeks gestation to 25 years (see
Table 1 and Materials and Methods). Our studies focused on the
DLPFC, an area implicated in higher cognitive function and in
which NMDAR hypofunction has been hypothesized in the
pathophysiology of schizophrenia.
Consistent with previous rodent studies, we found highly
regulated expression of NR3A during prenatal and postnatal
cortical development for both mRNA and protein levels (Fig. 2).
NR3A mRNA expression was shown to be significantly
regulated across the various age groups (ANOVA: F6,35 = 8.60,
P < 0.0001). Post hoc analyses indicate that NR3A transcript
levels are significantly reduced prenatally compared with the 0-
to 1-year group (P < 0.0001), the 1- to 5-year group (P < 0.05),
and the 11- to 15-year group (P < 0.01). Furthermore, we
observed a statistically significant decline in NR3A from the
peak expression of NR3A mRNA (0- to 1-year group) compared
with the 1- to 5-year group (P < 0.02), the 6- to 10-year group
(P < 0.001), the 11- to 15-year group (P < 0.02), the 16- to 20-
year group (P < 0.01), and the 21- to 25-year group (P <
0.0001). These data demonstrate that NR3A transcription is
weak embryonically, increases dramatically in the first year of
life, and then declines progressively into adulthood. NR3A
mRNA expression levels increased 10-fold from the fetal
samples as compared with the age group with peak expression.
Figure 1. Protein stability of NMDA receptor subunits (NR1, NR3A, NR2A, and
NR2B) and loading controls (b-Tubulin and GAPDH) in postmortem mouse frontal
cortex, normalized to the average of PMI 5 0 (n 5 4/group except n 5 2/group for
GAPDH). Data are presented as means ± standard error of the mean. Significance
from PMI 5 0 h: *P \ 0.05, **P \ 0.01, ***P \ 0.001. Representative
immunoblots are shown in addition to averaged data.
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In a secondary analysis, we performed an ANCOVA covarying
PMI and storage time across the different age groups (ANOVA:
F6,33 = 6.84, P < 0.0001). The results were largely consistent
with the previous analysis run without covariates, as post hoc
tests indicated that fetal tissue was significantly reduced
compared with the same older age groups as described above
(P < 0.05). Moreover, the peak expression of NR3A mRNA (0–1
year) was significantly greater than that at 16–20 years
(P < 0.02) and 21–25 years (P < 0.01). Unlike the primary
analysis, peak expression compared with 1- to 5-year, 6- to 10-
year, and 11- to 15-year age groups was not significant.
Strikingly, developmental changes in NR3A protein abun-
dance were qualitatively similar to that of NR3A mRNA levels.
After low prenatal expression, a sharp postnatal increase in
band densities was followed by a progressive reduction in
NR3A protein levels through childhood and adolescence (Fig.
2). A 1-way ANOVA detected a significant effect of age on NR3A
expression (F6,38 = 5.60, P <0.001). Subsequent Tukey–Kramer
post hoc tests revealed that prenatal and young adult (ages 21–
25 years) tissues expressed significantly less NR3A than infants
aged 0–1 year (P <0.001 and P <0.01, respectively). Also,
prenatal values differed significantly from age groups 1–5 and
6–10 (both P <0.05). The results of an ANCOVA covarying PMI
and storage time across the different age groups (ANOVA:
F6,36 = 4.72, P < 0.002) and post hoc tests were consistent
with the previous analysis, indicating that even with PMI and
storage time taken into account, the developmental differences
we observed were robust and still significant.
To examine NMDAR expression changes in another relevant
model system, where postmortem protein decay was not a
potential confound, we immunoblotted NMDAR subunit pro-
teins in developing postnatal macaque temporal cortex
(Supplementary Fig. S1A). Postmortem frozen cortical brain
tissue from 17 rhesus monkeys (Macaca mulatta) ages 3
months to 8 years were obtained from D.A. Lewis (University of
Pittsburgh). Although we were unable to acquire fetal macaque
tissue, our findings in monkeys show similar developmental
changes to those observed in human postnatal NR3A protein
expression (Fig. 2), with high expression in infancy that tapers
off into adulthood.
NR1 Levels Are Relatively High in the Developing Human
DLPFC
As the obligatory subunit of the NMDAR (Monyer et al. 1992;
Perez-Otano et al. 2001; Matsuda et al. 2003), NR1 serves as an
accurate gauge of the total number of NMDARs. Transcript and
protein levels of NR1 have been reported in various brain
regions in humans (Zhong et al. 1995; Akbarian et al. 1996;
Scherzer et al. 1998; Law et al. 2003; Clinton et al. 2006;
Kristiansen et al. 2006) and in rodents (Monyer et al. 1994;
Laurie et al. 1997; Goebel and Poosch 1999; Prybylowski and
Wolfe 2000; Sun et al. 2000; Ritter et al. 2002; Babb et al. 2005).
However, to our knowledge, no study has examined NR1
expression over development in human PFC.
To determine the normal developmental profile of NR1 mRNA
transcript and protein levels in the DLPFC, we again turned to
quantitative RT-PCR and immunoblotting (Fig. 3). NR1 mRNA
expression was shown to be significantly regulated across the
various ages (ANOVA: F6,35 = 8.26, P < 0.0001). As in the NR3A
quantitative PCR assays, there was a 10-fold increase in NR1
mRNA expression from prenatal to maximal postnatal levels.
Post hoc analyses revealed that in the group with the lowest
mRNA content (fetal samples), NR1 was significantly (P < 0.001)
reduced compared with samples from the age group in which
transcript levels were maximal, the 11- to 15-year group.
Furthermore, samples from the 0- to 1-year group (P < 0.01),
the 1- to 5-year group (P < 0.05), and the 6- to 10-year group (P
< 0.05) also were significantly reduced compared with the 11-
to 15-year group. In a secondary analysis, we performed an
ANCOVA covarying PMI and storage time across the binned age
groups (ANOVA: F6,33 = 6.73, P < 0.0001). As with the NR3A
secondary analyses, these results were consistent with the
Figure 2. NR3A mRNA and protein expression surges in DLPFC after birth and then
declines progressively. Quantification of NR3A levels, normalized to the average value
in the age group where NR3A expression was maximal (0–1 year). (A) Normalized
and averaged NR3A transcript levels binned into developmental age groups. (B)
Normalized and averaged NR3A protein expression data. Values within bars represent
sample sizes. Representative immunoblots are shown in addition to averaged data.
Data are presented as means ± standard error of the mean. Significance from age
group 0–1 year: *P\ 0.05, **P\ 0.01, ***P\ 0.001. (C) Scatter plot depicting
NR3A expression over development. The dashed line and gray shading divide prenatal
and postnatal tissue. Open circles and closed circles represent prenatal and postnatal
tissue, respectively. Some points are obscured by overlying points with similar values.
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primary analysis as well as subsequent post hoc analyses, sug-
gesting that PMI and storage time were independent from the
developmental differences we observed.
Western blot analyses of frontal cortical homogenates
prepared from the developmental samples demonstrate robust
expression of NR1. Consistent with NR1 mRNA, protein levels
are low prenatally and rise gradually to early adolescence and
then decline modestly into adulthood (Fig. 3). Protein
expression of NR1 was found to be significantly regulated
across developmental groups (ANOVA: F6,38 = 3.98, P < 0.005).
Post hoc tests indicate that the prenatal group was significantly
(P < 0.01) reduced compared with the 11- to 15-year group
and that there is a significant reduction (P < 0.02) of NR1
protein levels when comparing the 11- to 15-year group to the
21- to 25-year group. This reduction in adult tissue was not
observed with NR1 mRNA, suggesting that protein expression
may be regulated differently in maturity. An ANCOVA covarying
PMI and storage time across the different age groups found that
NR1 mRNA expression was significantly regulated across devel-
opmental groups (ANOVA: F6,36 = 2.86, P < 0.05). However,
post hoc tests revealed that, unlike the previous analysis, fetal
tissue failed to differ significantly from the 11- to 15-year group.
The observed significant (P < 0.01) decline in protein levels
comparing the 11- to 15-year group to the 21- to 25-year group
was maintained when including PMI and storage time as
covariates.
In a parallel study of cortical development, we probed fresh-
frozen postmortem tissue from developing postnatal macaque
cortex for NR1 protein (generous gift from D.A. Lewis,
University of Pittsburgh) (Supplementary Fig. S1B). Although
not statistically significant, developmental expression levels of
NR1 in monkeys appeared similar to that in humans, with high
levels exhibited until a drop during late puberty.
Because NR1 is essential for all functional NMDARs (Monyer
et al. 1992; Perez-Otano et al. 2001; Matsuda et al. 2003), the
ratio of NR3A to NR1 provides an estimate for the proportion
of NR3A-containing receptors out of the total pool of NMDARs
(Supplementary Fig. S2). By this measure, the NR3A/NR1 mRNA
ratio was shown to be significantly regulated across the various
age groups (ANOVA: F6,35 = 14.66, P < 0.0001). Post hoc
analyses indicate the peak NR3A/NR1 ratio of transcript levels
(0–1 year of age) was significantly different from all other
age groups. NR3A/NR1 levels are significantly reduced pre-
natally compared with the 0- to 1-year group (P < 0.0001).
Furthermore, we observed a statistically significant decline in
NR3A/NR1 ratio from peak expression (0- to 1-year group)
compared with the all other age groups (P < 0.0001). In
a secondary analysis, we performed an ANCOVA with PMI and
storage time as covariates across the different age groups
(ANOVA: F6,33 = 13.09, P < 0.0001). The results of this analysis
were consistent with the previous analysis run without
covariates.
The ratio of NR3A/NR1 protein similarly changed over de-
velopment (Supplementary Fig. S2). A 1-way ANOVA detected
a significant effect of age on NR3A/NR1 (F6,38 = 7.81, P <
0.0001). Subsequent Tukey–Kramer post hoc tests revealed
that prenatal tissue had a significantly lower NR3A/NR1 ratio
than infants aged 0–1 year and ages 1–5 (P < 0.0001 and P <
0.01, respectively). Furthermore, the maximum ratio of NR3A/
NR1 (0–1 year) differed significantly from all other age groups
(P < 0.01) except 1–5 years. From an ANCOVA covarying PMI
and storage time across the different age groups (ANOVA:
F6,36 = 7.27, P < 0.0001), our results were largely consistent
with the previous analysis as well as subsequent post hoc
analyses. Of the differences we observed, fetal expression was
no longer significantly different from the 1- to 5-year age group
and maximal expression did not differ substantially from the 6-
to 10-year age group. Overall, this impressive age-dependent
regulation of NR3A/NR1 mRNA and protein levels underscores
how vital the understanding of the ontogeny of these subunits
will be to investigations of how their dysregulation contributes
to neurodevelopmental disorders, such as schizophrenia or
bipolar disorder (Mueller and Meador-Woodruff 2004).
Figure 3. NR1 levels in human DLPFC change modestly over development. (A)
Normalized and averaged NR1 mRNA expression levels. (B) Normalized and averaged
NR1 protein expression data. Data are presented as means ± standard error of the
mean. Values within bars represent sample sizes. Representative immunoblots are
shown in addition to averaged data. Significance from age group 11–15 years: *P\
0.05, **P\ 0.01, ***P\ 0.001. (C) Scatter plot depicting NR1 levels over human
development. The dashed line and gray shading divide prenatal and postnatal tissue.
Open circles and closed circles represent prenatal and postnatal tissue, respectively.
Some points are obscured by overlying symbols with similar values.
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NR1 and NR3A Protein Levels Are Unchanged in
Schizophrenic DLPFC
A prominent theory of schizophrenia suggests that the disease
may arise from NMDAR hypofunction in the PFC (Javitt and
Zukin 1991; Tamminga 1998; Weickert and Weinberger 1998;
Olney et al. 1999; Lewis and Levitt 2002; Coyle et al. 2003;
Frankle et al. 2003). However, studies examining NR1 levels in
schizophrenia have found conflicting results (reviewed in
Kristiansen et al. 2007), suggesting that possible changes in
NR1 levels need further evaluation. To test whether protein
expression of NR1 is abnormal in the schizophrenic DLPFC
compared with tissue from comparison subjects (Table 2), we
probed immunoblots of human tissue homogenates to measure
NR1 protein (Fig. 4). A 2-way ANOVA (diagnosis 3 sex)
revealed no significant main effects on NR1 expression
(diagnosis F1,31 = 2.68, P = 0.11; sex F1,31 = 0.08; P = 0.78).
However, there was an interesting trend for an interaction
between diagnosis and sex (F1,31 = 3.32, P = 0.08) (Supple-
mentary Fig. S3), indicating that it might be worthwhile for
future studies to investigate sex differences in NR1 expression
in schizophrenic and control subjects.
To our knowledge, the NR3A subunit has been evaluated for
a role in schizophrenia in only one study, which demonstrated
that NR3A mRNA levels are significantly increased by 32%
within subregions of the DLPFC in schizophrenic patients
(Mueller and Meador-Woodruff 2004). We hypothesized that
schizophrenia could arise in part because of a failure of NR3A
to downregulate during development. Because NR3A sup-
presses calcium entry and NMDAR-mediated currents, higher
than normal NR3A levels would be expected to cause NMDAR
hypofunction. Thus, we sought to determine whether NR3A
levels were increased at the protein level in the DLPFC of the
schizophrenic brain (Fig. 4). Contrary to our hypothesis, there
was no main effect of diagnosis by a 2-way ANOVA (F1,31 = 0.53,
P = 0.47), indicating that NR3A levels are similar in control and
schizophrenic DLPFC. However, there was a significant main
effect of sex (F1,31 = 4.21, P < 0.05) (Supplementary Fig. S3),
suggesting that NR3A expression in the DLPFC is lower in
females compared with males. Storage time and PMI were not
statistically controlled because no significant differences were
observed between men and women regarding these variables.
Although these findings are intriguing, limited tissue availability
precluded our ability to further explore the possible gender-
related regulation of NR3A. To demonstrate that the lack of
effect of NR1 and NR3A on schizophrenia was not a conse-
quence of our standardization procedure, we also show similar
results by standardizing band densities to loading controls,
b-tubulin and GAPDH (see Supplementary Figs S4 and S5).
Antipsychotic Drugs Fail to Alter NMDAR Subunit
Expression
Antipsychotic drugs are standard treatments for schizophrenic
patients, primarily producing direct antagonistic effects on the
dopamine and serotonin systems. For example, haloperidol, a
typical antipsychotic, is a potent dopamine D2-like receptor
antagonist, whereas clozapine, an atypical antipsychotic, blocks
not only D2 but also serotonin receptors. Many drugs also
interact directly with the glutamate system, binding to
NMDARs (Ilyin et al. 1996; Gallagher et al. 1998) and affecting
NMDAR expression and activity (Ossowska et al. 1999; 2000;
Leveque et al. 2000; Schmitt et al. 2003; Bressan et al. 2005;
O’Connor et al. 2006). It was therefore important that we
examine how antipsychotics affect the expression of NMDAR
subunits.
To evaluate the possibility that differences in NMDAR sub-
units between controls and schizophrenics might have been
‘‘normalized’’ by antipsychotic drug usage, we measured
NMDAR subunit proteins in frontal cortical tissue from sub-
chronic drug-treated rats (Jarskog et al. 2007) (Fig. 5). Adult
rats were injected for 4 weeks with saline, haloperidol, or
clozapine, and immunoblotting was used to establish protein
levels from cortical homogenates. In our study, the drug
Figure 4. NMDAR subunit protein levels in control and schizophrenic subjects.
Scatter plots showing (A) NR1, (B) NR3A, and (C) NR3A/NR1. Small circles represent
data from individuals; large circles represent group means ± standard error of the
mean. Representative immunoblots are shown in addition to averaged data. CTL,
control (open circles); SCZ, schizophrenia (filled circles).
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treatments failed to modify NMDAR subunit levels, as indicated
by ANOVA (Fig. 5; 0.29 < F2,32 < 1.16, P > 0.32 for all subunits),
suggesting that antipsychotic treatments are unlikely to have
affected NR1 and NR3A protein levels observed in schizo-
phrenic patients.
Discussion
To our knowledge, this report provides the first evidence, in
any region of the human brain, for age-dependent differences
in NMDAR expression spanning the range from gestation to
early adulthood. We performed quantitative analyses of NMDAR
subunit mRNA and protein in postmortem human brain
sections from the DLPFC. Specifically, we demonstrate 1)
robust developmental regulation of NR3A and moderate devel-
opmental regulation of NR1, 2) close associations in abundance
of NR3A and NR1 transcript and protein levels, and 3) strong
parallels to previous findings in developing cortex in other
mammalian systems. Our results show that NR3A levels are low
prenatally, surge after birth, and then decrease progressively
into adulthood. These data indicate that NR3A serves a prom-
inent role in the development of the PFC soon after birth, and
its role is likely less prominent prenatally and in adulthood. In
contrast, NR1 levels rise from prenatal levels and vary only
modestly over development, supporting a lifelong importance
of NMDAR-dependent functions, including many forms of learn-
ing and memory. The defined expression patterns of these
particular subunits will increase our understanding of NMDAR-
mediated processes during ontogeny, will aid studies of
NMDAR dysfunction, and will guide the rational design of
subunit-specific NMDAR pharmacotherapies for neurological
disorders.
Importance of Age-Dependent Changes in NMDAR
Subunits to Normal Human Development
NMDAR subunits exhibit remarkable heterogeneity of expres-
sion. The significance of this molecular diversity is poorly
understood in humans, in part due to a lack of knowledge of
how these subunits change during development. Compared
with the rich literature describing developmental regulation of
NMDAR subunits in animal models, human developmental
studies have been largely limited to investigations at the mRNA
level (Law et al. 2003). Studies measuring mRNA must be
interpreted cautiously because protein and mRNA levels are not
always well correlated (Luo et al. 1996; Philpot et al. 2001). Thus,
we felt it essential to accurately describe both NMDAR mRNA
and protein levels in the human brain. By using quantitative RT-
PCR (Mimmack et al. 2004) and infrared immunoblot imaging,
we obtained highly sensitive detection of mRNA and protein
levels from postmortem tissues. Additionally, the samples
were binned into developmental age groups based on models
of cortical development, whichwas a hypothesis-drivenmeasure
to enable us to overlay the data onto findings from prior
investigations (Glantz et al. 2007; Salimi et al. forthcoming).
Although NR1 is obligatory for NMDAR function, the specific
properties of NMDARs are shaped by the combination of NR1
with NR2 and/or NR3 subunits. NR3A is the most recently
described NMDAR subunit and consequently its influence on
NMDAR properties is less well defined compared with the NR2
subunits. However, interest in this unique subunit has grown
recently with exciting observations that it acts in a novel,
dominant-negative manner to reduce calcium influx and the
unitary conductance of NMDAR currents (Ciabarra et al. 1995;
Sucher et al. 1995; Perez-Otano et al. 2001; Sasaki et al. 2002;
Figure 5. Antipsychotic drugs fail to alter NMDAR subunit levels, shown normalized to saline control values. Bar graphs depicting quantification of (A) NR1, (B) NR3A, (C) NR2A,
and (D) NR2B in frontal cortical tissue from antipsychotic-treated rats. Data are presented as means ± standard error of the mean. SAL, saline; HAL, haloperidol; and CLZ,
clozapine.
Cerebral Cortex November 2008, V 18 N 11 2567
Matsuda et al. 2003), thereby suppressing NMDAR function.
Here, we show that in human PFC NR3A levels peak during
early childhood and then decrease into adulthood. Animal
studies have established a similar developmental pattern of
NR3A expression (Ciabarra et al. 1995; Sucher et al. 1995; Das
et al. 1998; Sun et al. 1998; Al-Hallaq et al. 2002; Sasaki et al.
2002; Wong et al. 2002; Ishihama and Turman 2006; Perez-
Otano et al. 2006), suggesting that this might be a general
feature of mammalian brain development.
What functions might high levels of NR3A have during early
development? Based on in vitro and in vivo studies in animal
models, at least 6 nonmutually exclusive possibilities exist for
the function of NR3A during DLPFC development. 1) Given
that genetic deletion of NR3A in mice increases spine density
(Das et al. 1998), NR3A may regulate the formation of dendritic
spines, the major sites of excitatory synapses. Indeed, massive
spinogenesis and synaptogenesis in infancy and early child-
hood, as well as synapse elimination in adolescence, have been
demonstrated in both human (Huttenlocher 1979; Bourgeois
et al. 1994; Huttenlocher and Dabholkar 1997; de Graaf-Peters
and Hadders-Algra 2006; Glantz et al. 2007) and nonhuman
primate PFC (Rakic et al. 1986; Bourgeois et al. 1994; Anderson
et al. 1995; Gonzalez-Burgos et al. 2007). 2) Because NR3A
limits NMDAR-mediated calcium entry and its expression is
elevated during a period of intense programed cell death, NR3A
is positioned to actively influence apoptosis by attenuating
calcium-mediated excitotoxicity (Lipton and Nakanishi 1999).
On the other hand, because NMDAR antagonism can also lead
to cell death (Ikonomidou et al. 1999), excessive NR3A levels
could actually promote apoptosis. Thus, the relative balance of
NR3A expression might serve to control which cells are
targeted for cell death versus survival. 3) Calcium is a critical
mediator of both long-term depression and potentiation, which
are thought to be mechanistic substrates for learning and
memory (Malenka and Bear 2004). NR3A-dependent control of
calcium entry would be expected to dramatically shape the
properties of NMDAR-mediated plasticity, which could be
revealed in future studies through mutant mice that either lack
or overexpress NR3A (Das et al. 1998; Sucher et al. 2003; Brody
et al. 2005). 4) Exciting new data demonstrate that NR3A-
containing receptors appear to undergo rapid endocytosis that
is regulated in an activity-dependent manner by PACSIN1/
syndapin1 (Perez-Otano et al. 2006). Thus, NR3A may be
important for clearing immature synaptic NMDARs so that they
can be replaced by more mature receptors. 5) NR3A spe-
cifically forms a signaling complex with PP2A (Chan and Sucher
2001), a phosphatase that can dephosphorylate NR1 subunits
on serine 897. NR3A may indirectly modulate NMDAR function
through this interaction, and thus provide bidirectional control
of synaptic activity. 6) Uniquely, NR3A-containing receptors
lack strong blockade by magnesium at hyperpolarized poten-
tials (Ciabarra et al. 1995; Sucher et al. 1995; Das et al. 1998; Al-
Hallaq et al. 2002; Sasaki et al. 2002). Thus, although
speculative, a novel role for NR3A-containing NMDARs during
early life might be to support synaptic transmission at ‘‘silent
synapses’’ before there is an activity-dependent mobilization of
a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid recep-
tors to the synapse during maturation (Durand et al. 1996; Wu
et al. 1996; Isaac et al. 1997; Rumpel et al. 1998; Zhu et al. 2000;
Plitzko et al. 2001).
The observation that expression levels of the essential NR1
subunit increase progressively from prenatal stages and remain
relatively high throughout life is perhaps not surprising as
NMDAR function has been implicated in a variety of vital
functions, including learning and memory, neuronal migration,
synapse stabilization, pain perception, and neuronal cell death
(Komuro and Rakic 1993 and reviewed in Malenka and Nicoll
1999; Cull-Candy and Leszkiewicz 2004). These data are
consistent with that seen in other regions of the human brain
(Law et al. 2003) and observations in animal models (Watanabe
et al. 1992; Luo et al. 1996; Laurie et al. 1997; Chen et al. 2000;
Sans et al. 2000; Ritter et al. 2002; Awobuluyi et al. 2003; Ontl
et al. 2004; Petralia et al. 2005). NMDAR levels may also be
particularly high in the DLPFC as the PFC may contain the
highest concentration of NMDARs in the cortex (Scherzer et al.
1998). Notably, NMDAR-mediated functions are apparently
crucial even for embryonic life because genetic deletion of NR1
in mice leads to neonatal lethality (Forrest et al. 1994).
Whereas, we observed clear developmental regulation of
NR1 mRNA indicating a low prenatal level of expression com-
pared with later developmental age groups, we observed a
more modest increase in NR1 protein levels when comparing
prenatal to maximum expression (11–15 years). However,
when we performed a secondary analysis using PMI and storage
time as covariates, this difference in protein levels failed to
reach significance. Due to the modest developmental regula-
tion of NR1 compared with other NMDAR subunits, such as
NR3A, the detection of subtle differences in NR1 protein ex-
pression levels over development will require closer examina-
tion in future studies. We largely observed similar trends in
mRNA and protein expression in both NR3A and NR1. We did,
however, observe one inconsistency. Interestingly, whereas
NR1 transcript levels remain high in adult PFC, protein levels
drop significantly. Similar discrepancies between mRNA and
protein levels have been noted and may result from trans-
lational inefficiency or increased rates of protein degradation
(Awobuluyi et al. 2003; VanDongen AM and VanDongen HM
2004).
The abundant NR1 protein levels observed during childhood
are present during a period of extensive development of neu-
ronal processes and formation of synaptic connections (Webb
et al. 2001de Graaf-Peters and Hadders-Algra 2006). Why does
NMDAR expression peak around early adolescence in the
DLPFC? The elevated NR1 levels may provide a molecular
substrate for robust synaptic plasticity in cortical regions at this
time. The intriguing reductions in NR1 protein expression after
puberty parallel the loss of synapses observed in human PFC
and are consistent with a role for NMDARs in synaptic pruning
or elimination in humans (Huttenlocher and Dabholkar 1997;
Glantz et al. 2007) and in nonhuman primates (Bourgeois et al.
1994; Gonzalez-Burgos et al. 2007). Additionally, this might also
be associated with critical period closure for many forms of
NMDAR-mediated plasticity (Malenka and Bear 2004).
Currently little is known about NR3A in humans, but the
high level of homology between human and rodent NR3A
(93%) (Andersson et al. 2001; Eriksson et al. 2002) and the
strong overall relationship between NMDAR subunit mRNA and
protein levels found in this study suggest its function is likely
similar between mammalian species. To observe NMDAR
developmental changes without the issues of postmortem
degradation, we ran a parallel study in cortical tissue from
rhesus macaque, a close genetic relative of humans (Gibbs et al.
2007), and found broad similarities to the human studies
(Supplementary Fig. S1). Most importantly, the early peak in
2568 NR3A and NRI in Human Development d Henson et al.
NR3A protein expression that tapers into maturity coincides
with the developmental loss of NR3A in humans and rodents.
Thus, despite the unavoidable caveats associated with studying
human postmortem tissue, the similarities in the combined
human transcript and protein data and monkey protein results
produced from this study strengthen our conclusions and
support the view that NMDAR subunits are similarly modified
across development in rodents, nonhuman primates, and
humans.
We initially sought to characterize the subunits in postnatal
cortex: NR1, NR2A, NR2B, and NR3A (Watanabe et al. 1993;
Monyer et al. 1994; Sheng et al. 1994; Stocca and Vicini 1998).
Because all proteins are subject to decay after death, we first
established our ability to quantify NMDAR subunit levels in
postmortem tissue using immunoblotting (see Materials and
Methods). Although >65% of NR1 and NR3A remained intact
up to a 24 h PMI, less than 50% of the NR2A and NR2B levels
could be detected. This was consistent with our difficulty, and
that of others, in reliably measuring NR2A and NR2B levels in
human and nonhuman primate tissue (Wang et al. 2000;
O’Connor et al. 2006). Although we observed rapid decay of
NR2A and NR2B with these particular antibodies (see Materials
and Methods), protein degradation may differ among epitopes
or tissue preparation techniques. As such, antibodies or
approaches may exist that are better suited for detecting
NR2A and NR2B levels in tissue with long PMIs (see Murphy
et al. 2005; Kristiansen et al. 2006). Due to our difficulties in
detecting NR2A and NR2B levels, we focused on NR1 and NR3A.
Relevance of NR1 and NR3A Expression to Schizophrenia
Because NMDAR hypofunction has been hypothesized to
underlie some of the cognitive deficits observed in schizo-
phrenia (Javitt and Zukin 1991; Jentsch and Roth 1999; Olney
et al. 1999; Lewis and Levitt 2002; Coyle et al. 2003; Frankle
et al. 2003), we asked whether this could be due to alterations
in NMDAR subunit proteins within the DLPFC. Reports of
subunit modifications in schizophrenia are largely conflicting
(reviewed in Kristiansen et al. 2007). Our data reach the same
conclusions as Kristiansen et al. (2006), indicating that NR1
protein levels are unchanged in the schizophrenic brain. Subtle
changes in NR1 splice-variant expression (Prybylowski and
Wolfe 2000; Magnusson et al. 2005) might account for
alterations of the subunit but may not be detectable in our
system.
Recent data raised the intriguing possibility that NMDAR
hypofunction in schizophrenia might arise from an aberrant
increase in NR3A expression, as NR3A suppresses NMDAR func-
tion and NR3A mRNA transcript levels are significantly elevated
in the DLPFC of schizophrenic patients (Mueller and Meador-
Woodruff 2004). In this same region where NR3A is overex-
pressed, spine densities are reduced in schizophrenic patients
(Glantz and Lewis 2000). Because NR3A likely has a strong
influence on limiting spine density (Das et al. 1998), a lack of
the normal developmental downregulation of NR3A could re-
sult in significant reductions in spine numbers. Therefore, it is
appealing to hypothesize that NR3A levels are elevated in
schizophrenics, as this could explain both the NMDAR hypo-
function and the reductions in dendritic spine density that have
been observed.
However, our data provide the first evidence that schizo-
phrenia is not associated with a gross change in NR3A at the
protein level within the DLPFC. Given that NR3A expression is
normally very low in the adult human brain (this study) and
that subregion- and lamina-specific differences in the expres-
sion of NR3A exist (Mueller and Meador-Woodruff 2004; 2005;
Bendel et al. 2005), we cannot rule out the possibility that
there may be subtle or region-specific differences in NR3A
proteins that our methods were unable to detect. A more
selective analysis of synaptic membranes from different regions
and/or laminae have the potential to reveal significant differ-
ences in receptor protein expression in the schizophrenic
brain, if such differences exist.
Even in the absence of differences in adult NR3A protein
levels, other possibilities for NMDAR hypofunction involving
NR3A may exist. Genetic variants of NR3A could provide a
molecular substrate for abnormal NR3A function (Gallinat et al.
2007), particularly relevant for prefrontal information process-
ing. As schizophrenia is considered a neurodevelopmental
disorder, a transient increase of NR3A during development
could disturb the normal formation of cortical circuits yet not
be apparent in the adult brain (Lewis 1997). Because anti-
psychotic drugs can alter NMDAR subunit expression in a
region-specific manner (Fitzgerald et al. 1995; Hanaoka et al.
2003; Schmitt et al. 2003; O’Connor et al. 2006), we explored
the possibility that drug treatments might account for the
normal levels of NR3A and NR1 we found in schizophrenic
patients. After modeling the effects of subchronic clozapine
and haloperidol exposure in rodent frontal cortex, we found
that NMDAR subunit expression is unchanged, consistent with
previous observations (Hanaoka et al. 2003). Although we
cannot preclude the possibility that different antipsychotic
treatment regimens might alter NMDAR protein levels, our data
suggest that normal NR1 and NR3A protein levels in the DLPFC
of schizophrenic patients are unlikely to be consequences of
antipsychotic treatments. This suggests either that overall
NMDAR hypofunction in schizophrenia is not related to
widespread changes in NMDAR proteins or that such deviations
fail to be maintained throughout life in this brain region. We
argue that the NMDAR hypofunction observed in the disease is
not maintained by gross differences in total NMDAR number or
the proportion of NR3A-containing NMDARs, although there
may be more subtle laminar or regional effects.
In light of reports of gender influences in normal NMDAR
expression as well as in schizophrenia, we examined possible
gender differences in NR1 and NR3A. We observed marginal
significance for sex-based differences suggesting that females
have significantly less NR3A and a trend for less NR1 than their
male counterparts. The meaning of these results in human
DLPFC is unknown. However, there is a precedent for gender-
specific differences in NR1 expression within other regions of
the brain (Shi and Schlenker 2002; Ontl et al. 2004), suggesting
that NR1 levels are differentially regulated by sex hormones
(Gazzaley et al. 1996; McEwen 2002; McEwen 2002). Like NR1,
NR3A levels might also be regulated by sex hormones, such as
estrogen. Indeed, genetic deletion of NR3A impairs prepulse
inhibition, a measure of sensorimotor gating, in male but not
female mice (Brody et al. 2005). This finding suggests that es-
trogen might normally downregulate NR3A levels, thus mirror-
ing effects of genetic NR3A deletion in mice. Such an
interpretation would be consistent with our observation that
NR3A, and possibly NR1, levels are lower in the DLPFC of
females compared with males. It might also explain the
observation that there is a sex-specific difference in prepulse
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inhibition in normal human subjects (Swerdlow et al. 1993).
Interestingly, schizophrenics are known to exhibit deficits in
prepulse inhibition to startle (reviewed in Braff et al. 2001),
suggesting a potential link between sex-specific NMDAR sub-
unit expression and the schizophrenic condition. Although we
stress the preliminary nature of these gender-related observa-
tions, the possibility for reduced expression of NR3A in females
warrants more intense scrutiny, as it could provide a biological
basis to explain why female schizophrenic patients tend to
manifest symptoms at a later age, are more responsive to medi-
cations and exhibit less severe symptoms than males (Castle
and Murray 1991).
Although we attempted to carefully address the confounding
factors that are inherent to all human postmortem studies, one
of the main limitations to such investigations is the relatively
small numbers of postmortem brain samples available. How-
ever, even after considering such factors as PMI, pH, sex, eth-
nicity, and storage time on the quality of the mRNA and
proteins studied, we still found significant developmental
changes in NMDAR subunits, suggesting that the increases
and decreases in expression patterns are due to robust de-
velopmental regulation. The observed statistical differences in
developmental NMDAR subunit levels likely represent the most
dramatic and consistent age-dependent differences in subunit
levels. Analyses of additional tissue might reveal more subtle
developmental effects. It is important to note that the current
study represents the first developmental analysis of NMDA
receptors in human cortex from gestation to adulthood.
Developmental studies in human brain of key regulatory
systems—including glutamate—are needed to advance our
understanding of normal brain development and provide
insights into the pathophysiology of neurodevelopmental
disorders such as schizophrenia.
In summary, we report the developmental and schizophrenia
profiles of NMDA receptor subunits, NR1 and NR3A, in human
PFC. The data are consistent with lifelong functional roles for
NR1 and a particularly important role during early human brain
development for NR3A. Our results also suggest that there are
no gross differences in NR1 and NR3A protein levels between
schizophrenic and control DLPFC. Collectively, this study will
be relevant in understanding subunit functions in key NMDAR-
mediated processes of ontogeny, such as the formation and
refinement of cortical circuits. Additionally, these results con-
tribute to understanding subunit roles in disorders of NMDAR
dysfunction, such as the basis for NMDAR hypofunction in
schizophrenia, as well as subtype-specific targeting in drug
development.
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